[go: up one dir, main page]

DK3153508T3 - Naphthofuranderivater til anvendelse som anticancermidler - Google Patents

Naphthofuranderivater til anvendelse som anticancermidler Download PDF

Info

Publication number
DK3153508T3
DK3153508T3 DK15807132.4T DK15807132T DK3153508T3 DK 3153508 T3 DK3153508 T3 DK 3153508T3 DK 15807132 T DK15807132 T DK 15807132T DK 3153508 T3 DK3153508 T3 DK 3153508T3
Authority
DK
Denmark
Prior art keywords
naphthofurand
derivatives
anticancer agents
anticancer
agents
Prior art date
Application number
DK15807132.4T
Other languages
English (en)
Inventor
Yoshinobu Yoshimura
Masayasu Kasai
Yoshimichi Shoji
Shigemitsu Takeda
Original Assignee
Kyoto Pharma Ind
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto Pharma Ind, Sumitomo Dainippon Pharma Co Ltd filed Critical Kyoto Pharma Ind
Application granted granted Critical
Publication of DK3153508T3 publication Critical patent/DK3153508T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92Naphthofurans; Hydrogenated naphthofurans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06Heterocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
DK15807132.4T 2014-06-09 2015-06-09 Naphthofuranderivater til anvendelse som anticancermidler DK3153508T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014119113 2014-06-09
JP2015021492 2015-02-05
PCT/JP2015/066625 WO2015190489A1 (ja) 2014-06-09 2015-06-09 新規抗癌剤

Publications (1)

Publication Number Publication Date
DK3153508T3 true DK3153508T3 (da) 2020-05-18

Family

ID=54833579

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15807132.4T DK3153508T3 (da) 2014-06-09 2015-06-09 Naphthofuranderivater til anvendelse som anticancermidler

Country Status (8)

Country Link
US (4) US10005752B2 (da)
EP (1) EP3153508B1 (da)
JP (3) JP6549115B2 (da)
AU (1) AU2015272560B2 (da)
CA (1) CA2951627A1 (da)
DK (1) DK3153508T3 (da)
ES (1) ES2792851T3 (da)
WO (1) WO2015190489A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6433085B2 (ja) 2013-04-09 2018-12-05 ボストン バイオメディカル, インコーポレイテッド がんの処置に使用するための2−アセチルナフト[2,3−b]フラン−4,9−ジオン
WO2015190489A1 (ja) 2014-06-09 2015-12-17 京都薬品工業株式会社 新規抗癌剤
EA201792623A1 (ru) * 2015-06-03 2018-04-30 Бостон Биомедикал, Инк. Композиции, содержащие ингибитор стволовости рака и иммунотерапевтический агент, для применения в лечении рака
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
EP3592730B1 (en) 2017-03-09 2021-08-04 Truly Translational Sweden AB Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
CN109206390B (zh) * 2017-07-06 2021-04-27 北京大学 基于呋喃萘醌的亚砜亚胺衍生物及其在制造stat3抑制剂中的用途
CN110818662A (zh) * 2019-12-11 2020-02-21 肇庆市万维新材料科技有限公司 一种那布卡辛的合成方法
CN110818663A (zh) * 2019-12-12 2020-02-21 肇庆市万维新材料科技有限公司 一种那布卡辛同系物的合成方法
CN113214201B (zh) * 2021-03-22 2023-08-15 毕庶壮 一类Napabucasin的衍生物及其药物用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027443T2 (en) 2007-09-10 2016-10-28 Boston Biomedical Inc A novel class of Stat3 pathway inhibitors and tumor stem cell inhibitors
EP2419398A4 (en) 2009-04-14 2012-11-28 Infiniton Ab PRO-BET WITH BETA-KETO-CARBOXYLIC ACID, BETA-KETO-CARBOXYLIC ACID SALT OR BETA-KETO-CARBOXYLIC ACID ESTERS FOR ACTIVE INHIBITION
CN103002890A (zh) 2010-03-19 2013-03-27 波士顿生物医学公司 靶向癌症干细胞的新的化合物和组合物
CN103025159A (zh) * 2010-03-19 2013-04-03 波士顿生物医学公司 靶向癌症干细胞的新方法
EP2681203A4 (en) * 2011-03-04 2014-07-30 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co Ltd NOVEL 4,9-DIHYDROXY-NAPHTO [2,3-B] FURANS ESTERS FOR THERAPEUTIC TREATMENT OF DISEASES
CN104080449A (zh) 2012-02-17 2014-10-01 舟山海中洲新生药业有限公司 4,9-二羟基-萘并[2,3-b]呋喃脂肪酸酯衍生物的纳米颗粒水悬液的制备方法
WO2013166618A1 (en) 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
WO2015190489A1 (ja) 2014-06-09 2015-12-17 京都薬品工業株式会社 新規抗癌剤

Also Published As

Publication number Publication date
AU2015272560B2 (en) 2019-02-14
JPWO2015190489A1 (ja) 2017-05-25
US20170121299A1 (en) 2017-05-04
EP3153508A4 (en) 2017-11-15
US20190322636A1 (en) 2019-10-24
WO2015190489A1 (ja) 2015-12-17
JP2019206529A (ja) 2019-12-05
EP3153508A1 (en) 2017-04-12
AU2015272560A1 (en) 2017-02-02
JP6963262B2 (ja) 2021-11-05
US10689355B2 (en) 2020-06-23
JP6549115B2 (ja) 2019-07-24
US10377730B2 (en) 2019-08-13
JP2022008894A (ja) 2022-01-14
US20180265489A1 (en) 2018-09-20
US11267797B2 (en) 2022-03-08
ES2792851T3 (es) 2020-11-12
EP3153508B1 (en) 2020-03-18
CA2951627A1 (en) 2015-12-17
US10005752B2 (en) 2018-06-26
US20200317630A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
DK3094631T3 (da) Pyrimidinyloxybenzenderivater som herbicider
DK3229810T3 (da) Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler
DK3293186T3 (da) Pyrimidinoner som faktor xia-hæmmere
DK3131902T3 (da) Forbindelser som ROR-gamma-modulatorer
DK3461821T3 (da) Indolcarboxamidforbindelser, der er brugbar som kinasehæmmere
LT3134402T (lt) 4-amino-imidazochinolino junginiai
BR112016023628A2 (pt) composições farmacêuticas.
EP3226841C0 (en) ANTICANCER COMPOSITIONS
LT3204359T (lt) Tetrahidroizochinolino dariniai
DK3294713T5 (da) Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer
DK3226842T3 (da) Anticancersammensætninger
DK3325487T3 (da) Formulering til bløde, anticholinerge analoger
DK3153508T3 (da) Naphthofuranderivater til anvendelse som anticancermidler
DK3226843T3 (da) Anticancersammensætninger
DK3125898T3 (da) Farmakofor til trail-induktion
EP3311841A4 (en) ANTI CANCER AGENTS
HUE048321T2 (hu) Karabazol származékok
DK3231803T3 (da) Dihydroindolizinonderivat
DK3212237T3 (da) Methotrexatformulering
DK3131898T3 (da) Fluoroalkylfluorenderivativer
EP3140315C0 (en) NEW CATH2 DERIVATIVES
DK3145916T3 (da) Imidazolderivater som formylpeptidreceptormodulatorer
DK3191466T3 (da) Azetidinyloxyphenylpyrrolidinforbindelser
ZA201704462B (en) New benzimidazole derivatives as antihistamine agents
HUE039805T2 (hu) Új szulfonilaminobenzamid vegyületek